This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to AUPH stock based on the movements in the options market lately.
Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Company News for May 13, 2025
by Zacks Equity Research
Companies in The News Are: NRG,FOX,AUPH,HBM
Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 2.63%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
by Zacks Equity Research
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Are Options Traders Betting on a Big Move in Aurinia Pharmaceuticals (AUPH) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 200% and 0.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Corcept (CORT) Soars 13.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Corcept (CORT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Aurinia (AUPH) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aurinia (AUPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 400% and 14.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Aurinia (AUPH) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
Aurinia Pharmaceuticals (AUPH) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 100% and 4.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 82.35% and 8.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of -5.56% and 3.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.